Viatris Inc. Common Stock (VTRS)
Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Pfizer’s Upjohn unit. The company specializes in developing, manufacturing, and marketing a broad range of pharmaceuticals, including generic, branded, and biosimilar medicines, with a focus on improving access to affordable healthcare worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 15, 2025 | $0.12 | 2025-08-22 | 2025-08-22 |
| June 16, 2025 | $0.12 | 2025-05-23 | 2025-05-23 |
| March 18, 2025 | $0.12 | 2025-03-10 | 2025-03-10 |
| December 13, 2024 | $0.12 | 2024-11-22 | 2024-11-22 |
| September 13, 2024 | $0.12 | 2024-08-23 | 2024-08-23 |
Dividends Summary
- Viatris Inc. Common Stock has issued 18 dividend payments over the past 4 years
- The most recent dividend was paid 22 days ago, on September 15, 2025
- The highest dividend payed out to investors during this period was $0.12 per share
- The average dividend paid during this period was $0.12 per share.
Company News
The global epinephrine market is projected to grow from $2.77 billion in 2024 to $5.74 billion by 2032, driven by increasing cases of severe allergic reactions, technological advancements in auto-injectors, and rising awareness of anaphylaxis risks.
Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.
Goldman Sachs initiated coverage on several generic pharmaceutical stocks, highlighting Teva's branded drug growth and biosimilar pipeline as positives, while expressing neutrality on Viatris due to uncertainty around its core business. The firm also initiated Amneal with a Buy rating, citing its strong product pipeline and ability to offset pric...
Four stocks in the S&P 500 have a lower earnings multiple than the 4.9 percentage point gap between the average and median multiple of the index’s components. Click to read more.
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
